Effect of N‐Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy
Authors:
- 30 June 2019
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 59 (12) , 1678-1689
Abstract
Hydralazine, an antihypertensive agent used during pregnancy, undergoes N‐acetylation primarily via N‐acetyltransferase 2 (NAT2) to form 3‐methyl‐1,2,4‐triazolo[3,4‐a]phthalazine (MTP). To characterize the steady‐state pharmacokinetics (PK) of hydralazine during pregnancy and evaluate the effects of NAT2 genotype on hydralazine and MTP PK during pregnancy, 12 pregnant subjects received oral hydralazine (5‐25 mg every 6 hours) in mid‐ (n = 5) and/or late pregnancy (n = 8). Serial blood samples were collected over 1 dosing interval, and steady‐state noncompartmental PK parameters were estimated. Subjects were classified as either (rapid acetylators, n = 6) or slow acetylators (SAs, n = 6) based on NAT2 genotype. During pregnancy, when compared with the SA group, the RA group had faster weight‐adjusted hydralazine apparent oral clearance (70.0 ± 13.6 vs 20.1 ± 6.9 L/h, P < .05), lower dose‐normalized area under the concentration‐time curve (AUC; 1.5 ± 0.8 vs 5.9 ± 3.7 ng·h/mL, P < .05), lower dose‐normalized peak concentrations (0.77 ± 0.51 vs 4.04 ± 3.18 ng/mL, P < .05), and larger weight‐adjusted apparent oral volume of distribution (302 ± 112 vs 116 ± 45 L/kg, P < .05). Furthermore, the MTP/hydralazine AUC ratio was ∼10‐fold higher in the RA group (78 ± 30 vs 8 ± 3, P < .05) than in the SA group. No gestational age or dose‐dependent effects were observed, possibly because of the small sample size. This study describes for the first time, the PK of oral hydralazine and its metabolite, MTP, during pregnancy, and confirmed that the PK of oral hydralazine is NAT2 genotype dependent during pregnancy.Keywords
Funding Information
- National Center for Advancing Translational Sciences (UL1TR002319,)
- National Institute of General Medical Sciences (R01GM124264)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U10HD047892)
This publication has 62 references indexed in Scilit:
- Accuracy of Various Human NAT2 SNP Genotyping Panels to Infer Rapid, Intermediate and Slow Acetylator PhenotypesPharmacogenomics, 2011
- Orofacial Cleft Risk Is Increased with Maternal Smoking and Specific Detoxification-Gene VariantsThe American Journal of Human Genetics, 2007
- Antihypertensive Therapy in Pregnancy Directed by Noninvasive Hemodynamic MonitoringAmerican Journal of Perinatology, 1989
- Synthesis, Formulation, and Clinical Pharmacological Evaluation of Hydralazine Pyruvic Acid Hydrazone in two Healthy VolunteersJournal of Pharmaceutical Sciences, 1985
- Plasma concentration and acetylator phenotype determine response to oral hydralazine.Hypertension, 1981
- Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotypeJournal of Pharmacokinetics and Biopharmaceutics, 1980
- High-pressure Liquid Chromatographic Assay for Hydralazine in Human PlasmaJournal of Pharmaceutical Sciences, 1979
- Clinical Pharmacokinetics of HydrallazineClinical Pharmacokinetics, 1977
- 3-Hydroxymethyl-s-triazolo[3,4-a]phthalazine, a novel urinary hydralazine metabolite in manJournal of Medicinal Chemistry, 1975
- Elimination rate ofN-acetylprocainamide after a single intravenous dose of procainamide hydrochloride in manJournal of Pharmacokinetics and Biopharmaceutics, 1975